-
Navitoclax is an orally active Bcl-2 inhibitor targeting to Bcl-xL, Bcl-2, Bcl-w, with anti-tumor activity in vitro and in vivo. -
Salviolone is a natural diterpene identified from Salvia miltiorrhiza roots with an anti-melanoma activity. -
MMRi62, a Ferroptosis inducer targeting MDM2-MDM4. MMRi62 shows a P53-independent pro-apoptotic activity against PDAC cells. -
Mitonafide, a potent cytostatic agent, can inhibit DNA and RNA synthesis. Mitonafide is a potent antitumor agent. -
Olutasidenib (FT-2102) is an orally active, brain penetrant inhibitor of mutant IDH1. Olutasidenib is used for AML or MDS Research. -
JS25 is a selective and covalent BTK inhibitor in hematological cancer. JS25 has blood brain barrier crossing property. -
Purinostat mesylate is a potent and selective inhibitor of HDAC. Purinostat mesylate can be used for the research of lymphoblastic leukemia. -
TK4g is a potent JAK inhibitor and can be used for studies of lymphatic-related diseases and leukemic cancers. -
DD1, a proteasome inhibitor, targets Bax activation and P70S6K degradation during acute myeloid leukemia (AML) apoptosis. -
Daunorubicin is a topoisomerase II inhibitor with a wide spectrum of anticancer activity and anti-HBV effect.
Categories
Diseases
Others
Archives
- March 2023 (1)
- January 2023 (1)
- December 2022 (3)
- November 2022 (1)
- October 2022 (1)
- September 2022 (1)
- August 2022 (1)
- November 2021 (1)
- February 2020 (1)
- August 2019 (1)
- May 2019 (3)
- March 2019 (1)
